Immunosuppression in liver transplantation

Current Drug Targets

Volumn 10, Issue 6, 2009, Pages 557-574

  Mukherjee, Sandeep ^a   Botha, Jean F ^b   Mukherjee, Urmila ^c  

^a Section of Gastroenterology and Hepatology   (United States)

^b Section of Transplantation   (United States)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ALEMTUZUMAB; AMIODARONE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; JANUS KINASE 3 INHIBITOR; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ANEMIA; ANOREXIA; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; APHTHOUS ULCER; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTHRALGIA; ASEPTIC MENINGITIS; ASEPTIC NECROSIS; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CARBOHYDRATE DIET; CATARACT; CELL EXPANSION; CHRONOTROPISM; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; EOSINOPHILIA; EXOPHTHALMOS; FEMUR FRACTURE; FEVER; FLUID RETENTION; GASTRITIS; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GLAUCOMA; GLUCOSE INTOLERANCE; GRAFT REJECTION; GRAFT SURVIVAL; GRAPEFRUIT; GRAPEFRUIT JUICE; GROWTH RETARDATION; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFLAMMATION; INTERSTITIAL PNEUMONIA; INTRAOCULAR HYPERTENSION; LEUKOPENIA; LIPID DIET; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG EDEMA; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MENSTRUAL IRREGULARITY; MOOD DISORDER; MOON FACE; MUSCLE WEAKNESS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREATITIS; PEPTIC ULCER; PSEUDOTUMOR; PSYCHOSIS; RECURRENT DISEASE; REVIEW; SERUM SICKNESS; SIDE EFFECT; SINUS CONGESTION; SKIN BRUISING; SODIUM RETENTION; T LYMPHOCYTE ACTIVATION; TASTE DISORDER; THROMBOCYTOPENIA; UNITED STATES; VERTEBRA FRACTURE; VIRUS REPLICATION; VOMITING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANIMALS; DRUG INTERACTIONS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION;

EID: 68349147969     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009788488477     Document Type: Review

References (128)

1. Liver transplantation. National Institutes of Health Consensus Development. Natl Inst Health Consens Dev Conf Summ 1983; 4: 15.
2. Calne RY, White DJ, Thiru S, Rolles K, Drakopoulos S, Jamieson NV. Cyclosporin G: immunosuppressive effect in dogs with renal allografts. Lancet 1985; 1: 1342.
3. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. The US Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331: 1110.
4. Banff Working Group. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489-501.
5. Sharma VK, Li B, Khanna AS, Sehajpal PK, Suthanthiran M. Which way for drug mediated immunosuppression? Curr Opin Immunol 1994; 6: 784-90.
6. Gonwa TA, Mai ML, Melton LLB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy. Risk of development and treatment. Transplantation 2001; 72: 1934-9.
7. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
8. Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh JW, Reyes J, et al. Comparative incidence of de novo non-lymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193-1200.
9. Zheng H, Hin B, Henrickson SE, Perelson AS, von Andrian UH, Chakraborty AK. How antigen quantity and quality determine T cell decisions in lymphoid tissue. Mol Cell Biol 2008; 28: 4040-51.
10. Rubin B, Riond J, Leghait J, Gairin JE. Interactions between CD8 alphabeta and the TCR alphabeta/CD3-receptor complex. Scand J Immunol 2006; 64: 260-70.
11. Choudhuri K, Wiseman D, Brown MH, Gould K, van der Merwe PA. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature 2005; 436: 578-82.
12. O'Shea JJ, Johnston JA, Kehrl J, Koretzky G, Samelson LE. Key molecules involved in receptor-mediated lymphocyte activation. Curr Prot Immunol 2001; Chapter 11: Unit 11.9A.
13. 2003 Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients Annual Report: Transplant Data 1993-2002. US Department of Health and Human Services, Health Resources and Services Administration, Special Programs Bureau, Division of Transplantation; United Network of Organ Sharing; University Renal Research and Education Association (Table 9.6). Available at: http://www.ustransplant.org/ cgi-bin/ar?p=data_tables_10.htm&y=2003.
14. Kaufman D, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB. Immunosuppression: practice and trends. Am J Transplant 2004; 4: 38-53.
15. Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporine A: A new antilymphocytic agent. Agents Action 1976; 6: 468-75.
16. Starzl TE, Koep L, Porter KA, Schroter GP, Weil R 3rd, Hartley RB, et al. Decline in survival after liver transplantation. Arch Surg 1980; 115: 815-9.
17. Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GP. Liver transplantation with use of cyclosporin a and prednisone. N Eng J Med 1981; 305: 266-9.
18. Calne RY. Liver transplantation. Ann Clin Res 1981; 13: 327-35.
19. Gordon RD, Shaw BW, Iwatsuki S, Esquivel CO, Starzl TE. Indications for liver transplantation in the cyclosporine era. Surg Clin North Am 1986; 66: 541-56.
20. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of FK506, a novel immunosuppressant isolated from Streptomyces tsukabaensis. Transplant Proc 1987; 19: 4-8.
21. Hong F, Lee J, Piao YJ, Jae YK, Kim YJ, Oh C, et al. Transgenic mice overexpresing cyclophilin A are resistant to cyclopsorin A-induced nephrotoxicity via peptidyl-prolyl cis-trans isomerase activity. Biochem Biophys Res Commun 2004; 316: 1073-80.
22. Murakami Y, Tanaka T, Murakami H, Tsujimoto M, Ohtani H, Sawada Y. Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. Br J Clin Pharmacol 2006; 61: 671-6.
23. Todo S, Fung JJ, Starzl TE, Tzakis A, Doyle H, Abu-Elmagd K, et al. Single center experience with primary orthotopic liver transplantation under FK506 immunosuppression. Ann Surg 1994; 220: 297-308.
24. Fung JJ, Eliasziw M, Todo S, Jain A, Demetris AJ, McMichael JP, et al. The Pittsburgh randomized trial of tacrolimus versus cyclosporine for liver transplantation. J Am Coll Surg 1996; 183: 117-125.
25. European FK506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344: 423-8.
26. O'Grady JG, Hardy P, Burroughs AK, Elbourne D. UK and Ireland Liver Transplant Study Group. Randomized controlled trial of tacrolimus versus micremulsified cyclosporine (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137-41.
27. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6: 1578-85.
28. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; 4: CD005161.
29. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006; 131: 1452-62.
30. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51-7.
31. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-9.
32. Morgan JA. The influence of cortisone on the survival of homografts of skin in the rabbit. Surgery 1951; 30: 506-15.
33. Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385-95.
34. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268: 1315-23.
35. Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884-8.
36. Vivarelli M, Burra P, Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007; 47: 793-8.
37. Brown RS, Jr. Steroids in recurrent hepatitis C following liver transplantation: pitfall or panacea? J Hepatol 2007; 47: 741-3.
38. Neuhaus P, Krupp JJ, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001; 7: 473-84.
39. Raught B, Gingras AC, Gygi SP, Niedzwiecka A, Miron M, Burley SK, et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translational factor 4GI. EMBO J 2000; 19: 434-44.
40. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-8.
41. Zhu J, Wu J, Frizell E, Bashey R, Rubin R, Norton P, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117: 1198-204.
42. Levy GA, Drant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl] rapamycin in de novo liver transplant recipients. Transplantation 2001; 71: 160-3.
43. Holt DW, Lee T, Jones K, Johnston A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 2000; 46: 1179-83.
44. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67: 1036-42.
45. Trotter JF, Wachs ME, Trouillot WE, Bak T, Kugelmas M, Kam I, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7: 401-8.
46. Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathiprine for reduction of renal allograft rejection. Lancet 2000; 356: 194-202.
47. Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 1998; 20: 123-33.
48. Flores-Franco RA, Luevano-Flores E, Gaston-Ramirez C. Sirolimus associated desquamative interstitial pneumonia. Respiration 2007; 74: 237-8.
49. Neff GW, Ruiz P, Madariago JR, Nishida S, Montalbano M, Meyer D, et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 2004; 38: 1593-6.
50. Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555-61.
51. Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003; 9: 463-8.
52. Fung JJ, Marcos A. Rapamycin: friend, foe, or misunderstood? Liver Transpl 2003; 9: 469-72.
53. Fridell JA, Jain AK, Patel K, Virji M, Rao KN, Fung JJ, et al. Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report. Ther Drug Monit 2003; 25: 117-9.
54. Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 505-09.
55. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376-7.
56. Pridohl O, Heinemann K, Hartwig T, Witzigmann H, Lamesch P, Fangmann J, et al. Low-dose immunosuppression with FK-506 and sirolimus after liver transplantation: 1 year results. Transplant Proc 2001; 33: 3229-31.
57. McAlister VC, Peltekian KM, Malatjian DA, Colohan S, Mac-Donald S, Bitter-Suermann H, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701-8.
58. MacDonald AD. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas and kidney transplantation. Transpl Proc 2003; 35: 201S-208S.
59. Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343-51.
60. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079-85.
61. Casas-Melley AT, Falkenstein KP, Flynn LM, Ziegler VL, Dunn SP. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr Transplant 2004; 8: 362-6.
62. Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694-702.
63. Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007; 83: 1389-92.
64. Dubay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G, et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low dose calcineurin inhibitor regimens. Liver Transpl 2008; 14: 651-9.
65. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443-a potent new immunosuppressive agent. Transplantation 1991; 51: 27-31.
66. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921-30.
67. Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immuosuppressive agent. Am J Health Syst Pharm 1991; 54: 285-94.
68. Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant recipients treated with tacrolimus. J Clin Pharmacol 2001; 41: 268-76.
69. Stegal MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 1755-60.
70. Klupp J, Bechstein WO, Platz KP, Keck H, Lemmens HP, Knoop M, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation-first results. Transpl Int 1997; 10: 223-8.
71. Barkmann A, Nashan B, Schmidt HH, Böker KH, Emmanouilidis N, Rosenau J, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibition by mycophenolate mofetil. Transplantation 2000; 69: 1886-90.
72. Jain AB, Hamad IS, Rakela J, Dodson F, Kramer D, Demetris J, et al. A prospective randomized controlled trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998; 66: 1395-8.
73. Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, et al. Mycophenolate mofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003; 76: 130-6.
74. Akamatsu N, Sugawara Y, Tamura S, Matsui Y, Kaneko J, Makuuchi M. Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation. World J Gastroenterol 2006; 12: 4870-2.
75. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospectively randomized trial of mycophenolate mofetil in liver transplant recipients with recurrent HCV. Liver Transpl 2002; 8: 40-6.
76. Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine in allograft function and viral load in liver transplant recipients with recurrent HCV. Liver Transpl 2004; 10: 52-7.
77. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11: 750-9.
78. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant recipients with renal dysfunction: a randomized controlled study. Lancet 2001; 357: 587-91.
79. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609-10.
80. Starzl TE, Koep LJ, Halgrimson CG, Hood J, Schröter GP, Porter KA, et al. Liver transplantation-1978. Transplant Proc 1979; 11: 240-6.
81. Kung P, Goldstein G, Reinherz E, Schlossman F. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206: 347-9.
82. Chinnakotla S, Klintmalm G. Induction and maintenance of immunosuppression. In: Transplantation of the Liver, Bussutil R and Klintmalm G (eds), Elsevier Saunders, Philadelphia 2005. p 1213.
83. McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, et al. Increased risk for post transplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000; 6: 570-5.
84. Sanchez EQ, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002; 8: 285-91.
85. Kremers, WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6: 1017-24.
86. Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL. A randomized trial comparing OKT3 and steroids for the treatment of hepatic allograft rejection. Transplantation 1987; 43: 91-5.
87. Farges O, Ericzon BG, Bresson-Hadni S, Lynch SV, Höckerstedt K, Houssin D, et al. A randomized trial of OKT3-based versus cyclosporine- based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study. Transplantation 1994; 54: 891-8.
88. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-7.
89. Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994; 57: 685-94.
90. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657-62.
91. Mueller TM. Thymoglobulin: an immunologic overview. Curr Opin Organ Transplant 2003; 8: 305-12.
92. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001; 7: 693-7.
93. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396-9.
94. Nair S, Loss GE, Cohen AJ, Eason JD. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006; 81: 620-2.
95. De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, et al. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005; 80: 8-12.
96. Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs 2003; 63: 1229-43.
97. Calne RY. Prope tolerance: a step in the search for tolerance in the clinic. World J Surg 2000; 24: 793-6.
98. Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, et al. Prope tolerance, perioperative Campath 1H, and low dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-2.
99. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, et al. Results from a human renal allogaft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 2003; 76: 120-9.
100. Tzakis AG, Tryphonopoulos P, Kato T, Nishida S, Levi DM, Madariaga JR, et al. Preliminary experience with Alemtuzumab (Campath-1H) and low-dose Tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77: 1209-14.
101. Knechtle SJ, Pirsch JD, Fechner J Jr, Becker BN, Friedl A, Colvin RB, et al. Campath-1H induction plus rapamycin monotherapy in renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-30.
102. Vincenti F. Targeting the interleukin-2 receptor in clinical renal transplantation. Graft 1999; 2: 56-61.
103. Moser AJM. Options for induction immunosuppression in liver transplant recipients. Drugs 2002; 62: 995-1011.
104. Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2-receptor antibody in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8: 123-31.
105. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized controlled trial. Liver Transpl 2002; 8: 132-42.
106. Kwekkeboom J, Warle MC, Rietveld J, Segeren KC, Tilanus HW, Metselaar HJ. Blockade of intragraft IL-2 receptor-alpha by basiliximab is insufficient to prevent activation of liver graft infiltrating cells. Transpl Immunol 2003; 11: 728-33.
107. Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, et al. Double-blind comparison of hepatitis C histological recurrence in HCV+ liver transplant recipients given basilixmab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488-95.
108. Schmeding M, Sauer IM, Kiesling A, Pratschke J, Neuhaus R, Neuhaus P, et al. Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. Ann Transplant 2007; 12: 15-21.
109. Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, et al. Use of daclizumab as initial immuosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001; 7: 220-5.
110. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, et al. The safety and efficacy of a two-dose daclizumab induction therapy in liver transplant patients. Transplantation 2000; 69: 1867-72.
111. Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69: 307-11.
112. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 84: 829-35.
113. Klintmalm G, Fasola CG, Jennings L, Heffron TG, Sher L, Mulligan D, et al. Hepatitis C-3 study: does immunosuppression affect the progression of fibrosis of HCV recurrence after liver transplantation. Hepatology 2007; 46: abstract 7.
114. Birsan T, Dambrin C, Klupp J, Stalder M, Fitzsimmons WE, Morris RE. Effects of the malononitrilamide FK778 in immune functions in vitro in whole blood from non-immune primates and healthy human volunteers. Transpl Immunol 2003; 11: 163-7.
115. Bilolo KK, Ouyang J, Wang X, Zhu S, Jiang W, Qi S, et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation 2003; 75: 1881-7.
116. Jin MB, Nakayama M, Ogata T, Fujita M, Mino K, Taniguchi M, et al. A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. Surgery 2002; 132: 72-9.
117. Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW, Chong AS, Waldman WJ. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 71: 170-4.
118. Savikko J, von Willenbrand E, Hayry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effects: potential application for restenosis and chronic rejection. Transplantation 2003; 76: 455-8.
119. Vanrenterghem Y, van Hooff JP, Klinger M, Wlodarczyk Z, Squifflet JP, Mourad G, et al. The effects of FK778 in combination with Tacrolimus and steroids: a phase 2 multicenter study in renal transplant patients. Transplantation 2004; 78: 9-14.
120. O'Shea JJ. Jaks, STATs, cytokine signal transduction and immunoregulation: are we there yet? Immunity 1997; 7: 1-11.
121. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298: 1630-34.
122. Borie DC, Changelian PS, Larson MJ, Si MS, Paniagua R, Higgins JP, et al. Immunosuppression by the JAK3 inhibitor CP690,550 delays rejection and significantly prolongs renal allograft survival in non-human primates. Transplantation 2005; 79: 791-801.
123. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875-878.
124. Saemann MD, Zeyda M, Diakos C, Szekeres A, Böhmig GA, Kelemen P, et al. Suppression of early T-cell receptor triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 2003; 75: 1864-72.
125. Brinkmann V, Cyhster JG, Hla T. FTY720: sphingosine 1phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019-1025.
126. Anselmo DM, Amersi FF, Shen XD, Gao F, Katori M, Lassman C, et al. FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am J Transplant 2002; 2: 843-849.
127. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, et al. Rational development of LEA29Y (belatacept), a high affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-53.
128. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, et al. Co-stimulation blockade with belatacept in renal transplantation. N Eng J Med 2005; 353: 770-81.